在充满挑战的市场环境下，Alector Inc (ALEC)股价触及新的52周低点，跌至1.59美元。这一显著下跌反映了该生物科技公司的整体趋势，过去一年股价已下跌了75.15%。根据 InvestingPro ...

在充满挑战的市场环境下，Alector Inc (ALEC)股价触及52周新低，跌至1.59美元。根据InvestingPro分析，尽管面临重大阻力，但该公司目前市值1.5865亿美元的股票被认为估值偏低。这一价格水平反映出该生物科技公司的严重下滑，过去一年股价跌幅达71.53%。尽管投资者对公司在竞争压力和不断变化的医疗保健环境中的表现持谨慎态度，但 InvestingPro ...

In a challenging market environment, Alector Inc (NASDAQ:ALEC) stock has touched a new 52-week low, with shares plummeting to $1.59. This significant downturn reflects a broader trend for the ...

北京时间2025年01月31日02时20分，Alector, Inc.（ALEC.us）股票出现异动，股价急速拉升5.18%。截至发稿，该股报1.73美元/股，成交量 ...

北京时间2025年01月29日02时36分，Alector, Inc.（ALEC.us）股票出现异动，股价大幅下跌5.17%。截至发稿，该股报1.65美元/股，成交量25.4954万股， 换手率 0.26%，振幅4.31%。

Alector, Inc., a late-stage clinical biotechnology company, is advancing its preclinical and research pipeline focused on genetically-validated therapies for neurodegenerative diseases.

Alector, Inc. has a 52-week low of $1.55 and a 52-week high of $7.58. The stock has a market cap of $163.54 million, a price-to-earnings ratio of -0.98 and a beta of 0.61. Analyst Upgrades and ...

11月26日｜美国生物制药公司Alector(ALEC.US)盘前跌超33.5%，报2.63美元。消息面上，Alector表示，该公司的实验性药物在一项中期试验中没有达到减缓阿尔 ...

Shares of Alector, Inc. (NASDAQ:ALEC – Get Free Report) have received a consensus rating of “Hold” from the seven research firms that are presently covering the firm, MarketBeat Ratings reports.

Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company’s commitment to developing genetically ...

As of September 30, 2024, Alector had $457.2 million in cash, cash equivalents, and investments, which the company continues to expect will provide runway through 2026. Alector plans to provide ...